

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 22, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933 AND
THE SECURITIES EXCHANGE ACT OF 1934**

ANI Pharmaceuticals, Inc.

**File Nos. 333-87542, 000-28637 and 001-31812
CF#32317**

ANI Pharmaceuticals, Inc. formerly BioSante Pharmaceuticals, Inc. submitted an application under Rule 406 and Rule 24b-2 requesting an extension of prior grants of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 16, 2011, Form 10-K filed on March 27, 2007, Form SB-2 filed May 3, 2002, as amended, Form 10-KSB filed on March 28, 2002 and Form 8-K filed on July 11, 2000.

Based on representations by ANI Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

| Exhibit | to Form | Filed on | Confidential Treatment Granted |
|--|----------------|-----------------|---------------------------------------|
| 10.27 | 10-K | March 16, 2011 | through March 31, 2020 |
| 10.28 | 10-K | March 16, 2011 | through March 31, 2020 |
| 10.30 | 10-K | March 16, 2011 | through March 31, 2020 |
| 10.31 | 10-K | March 16, 2011 | through March 31, 2020 |
| 10.33 | 10-K | March 16, 2011 | through March 31, 2020 |
| 10.27 | 10-K | March 27, 2007 | through March 31, 2020 |
| (as re-filed with fewer redactions as Exhibit 10.33 to Form 10-K filed March 16, 2011) | | | |
| 10.20 | SB-2 | May 3, 2002 | through March 31, 2020 |
| (as re-filed with fewer redactions as Exhibit 10.31 to Form 10-K filed March 16, 2011) | | | |
| 10.18 | 10-KSB | March 28, 2002 | through March 31, 2020 |
| (as re-filed with fewer redactions as Exhibit 10.28 to Form 10-K filed March 16, 2011) | | | |
| 10.19 | 10-KSB | March 28, 2002 | through March 31, 2020 |
| 10.20 | 10-KSB | March 28, 2002 | through March 31, 2020 |
| (as re-filed with fewer redactions as Exhibit 10.30 to Form 10-K filed March 16, 2011) | | | |
| 10.1 | 8-K | July 11, 2000 | through March 31, 2020 |
| (as re-filed with fewer redactions as Exhibit 10.27 to Form 10-K filed March 16, 2011) | | | |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary